Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In patients with acute ischaemic stroke (AIS) intravenous thrombolysis with alteplase (t-PA) is the only effective treatment and it is approved within three or four and a half hours of symptom onset based on regulatory area. This study looked at how treatment delay, patient age and stroke severity influence the effect of t-PA in AIS in terms of functional outcome, mortality and intracranial haemorrhage (ICH).
This was a preplanned meta-analysis of individual patient data from nine randomised clinical trials of intravenous alteplase for AIS. The primary efficacy measure was the proportion of patients who achieved a 3–6 month good outcome per modified Rankin Scale score 0–1. Secondary outcomes …
Competing interests SL served as expert consultant for Boehringer Ingelheim.
Provenance and peer review Commissioned; internally peer reviewed.